CONTENTS:
- When harms outweigh benefits of long-term opioid therapy for pain: Need for a new diagnostic entity, research and improved treatments [Editorial]. Becker W.C., Frank J.W., Edmond S.N., Starrels J.L., p. 4-5.
- In the balance: No new diagnosis needed in addition to opioid use disorder to study harms associated with long-term opioid therapy [Editorial]. Drexler K., Edens E.L., Trafton J.A., Compton W.M., p. 6-8.
- New perspectives on how to formulate alcohol drinking guidelines [Addiction opinion and debate]. Shield K., Paradis C., Butt P., Naimi T., Sherk A., Asbridge M., et al., p. 9-19.
- Improving the epidemiology of low-risk drinking guidelines is not enough. Livingston M., p. 20-21.
- Debating Shield et al.'s perspectives on how to formulate alcohol drinking guidelines. Greenfield T.K., p. 22-23.
- The unacceptability of evidence on acceptable risks. Holmes J., Angus C.R., p. 24-25.
- New perspectives on how to formulate alcohol drinking guidelines: Response to commentaries. Shield K.D., Paradis C., Butt P.R., Naimi T., Sherk A., Asbridge M., et al., p. 26-27.
- A systematic review and meta-analysis of the relationship between youth drinking, self-posting of alcohol use and other social media engagement (2012-21). Cheng B., Lim C.C.W., Rutherford B.N., Huang S., Ashley D.P., Johnson B., et al., p. 28-46.
- Alcohol use in multiracial American youth compared with monoracial youth: A meta-analysis. Dobani F., Zaso M., Desalu J.M., Park A., p. 47-59.
- Commentary on Dobani et al.: Multiracial-A growing demographic for whom further research in the addiction field is warranted. Nalven T., Spillane N.S., p. 60-61.
- US tobacco companies selectively disseminated hyper-palatable foods into the US food system: Empirical evidence and current implications. Fazzino T.L., Jun D., Chollet-Hinton L., Bjorlie K., p. 62-71.
- Commentary on Fazzino et al.: Proof for why we need cross-industry approaches to research on the commercial determinants of health. Crosbie E., Schmidt L., p. 72-73.
- Household vaping bans and youth e-cigarette use. Staff J., Mongilio J.M., Maggs J.L., Vuolo M., Kelly B.C., p. 74-83.
- Commentary on Staff et al.: Should smoke-free areas be made vape-free? Tattan-Birch H., p. 84-85.
- Behavioural self-control training versus motivational enhancement therapy for individuals with alcohol use disorder with a goal of controlled drinking: A randomized controlled trial. Hammarberg S.I., Wallhed Finn S., Rosendahl I., Andréasson S., Jayaram-Lindström N., Hammarberg A., p. 86-101.
- Craving modulates attentional bias towards alcohol in severe alcohol use disorder: An eye-tracking study. Bollen Z., Pabst A., Masson N., Wiers R.W., Field M., Maurage P., p. 102-112.
- Brain structural covariance network features are robust markers of early heavy alcohol use. Ottino-Gonzalez J., Cupertino R.B., Cao Z., Hahn S., Pancholi D., Albaugh M.D., et al., p. 113-124.
- The estimated health impact of alcohol interventions in New Zealand: A modelling study. Chambers T., Mizdrak A., Herbert S., Davies A., Jones A., p. 125-136.
- Cannabis use disorder and adverse cardiovascular outcomes: A population-based retrospective cohort analysis of adults from Alberta, Canada. Bahji A., Hathaway J., Adams D., Crockford D., Edelman E.J., Stein M.D., et al., p. 137-148.
- Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder. Foot C., Korthuis P.T., Tsui J.I., Luo S.X., Chan B., Cook R.R., p. 149-157.
- Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder. Shulman M., Greiner M., Bisaga A., p. 158-159.
- Identifying patients with opioid use disorder using International Classification of Diseases (ICD) codes: Challenges and opportunities. Osterhage K.P., Hser Y.I., Mooney L.J., Sherman S., Saxon A.J., Ledgerwood M., et al., p. 160-168.
- Effects of the Connections program on return-to-custody, mortality and treatment uptake among people with a history of opioid use: Retrospective cohort study in an Australian prison system. Sullivan E., Zeki R., Ward S., Sherwood J., Remond M., Chang S., et al., p. 169-179.
- Drug consumption rooms are effective to reduce at-risk practices associated with HIV/HCV infections among people who inject drugs: Results from the COSINUS cohort study. Lalanne L., Roux P., Donadille C., Briand Madrid L., Célerier I., Chauvin C., et al., p. 180-199.
- Commentary on the current state of perioperative and critical care buprenorphine management. Quaye A., Crist C., Matoi S., Zhang Y., p. 200-201.
- Not all kratom is equal: The important distinction between native leaf and extract products. Grundmann O., Garcia-Romeu A., McCurdy C.R., Sharma A., Smith K.E., Swogger M.T., et al., p. 202-203.